We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App




Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities

By LabMedica International staff writers
Posted on 29 Sep 2025

Oxidative stress has been linked to cellular damage involving proteins, DNA, and lipids, and it plays a role in conditions such as cardiovascular disorders, diabetes, neurodegenerative diseases (Alzheimer’s and Parkinson’s), cancer, and chronic infections. More...

Detecting and monitoring oxidative stress biomarkers is essential for both clinical diagnostics and research, yet current tools remain fragmented and limited in reach. To address this, a major acquisition is set to expand global access to advanced diagnostic solutions and research tools.

Lumiquick Diagnostics (Santa Clara, CA, USA), a developer and manufacturer of in vitro diagnostic (IVD) tests, has acquired AOXRE LLC (Burlingame, CA, USA), which is recognized for its innovative OxisResearch product line. At the heart of the OxisResearch product line are the Bioxytech assay kits targeting oxidative and nitrosative stress biomarkers.

With this acquisition, customers can expect the full product line of oxidative stress markers and companion diagnostic assays, including Cellular Damage Monitoring, REDOX balance assessment, ELISA, and rapid test of various biological markers that are associated with the oxidation status of the human body.

This strategic acquisition marks a significant milestone for Lumiquick as it continues to expand its global footprint and product portfolio in the IVD & research industries. AOXRE’s expertise, technology, and customer relationships will be fully integrated into Lumiquick’s operations, strengthening the company’s position as a comprehensive provider of high-quality diagnostic and research tools.

“We are thrilled to welcome AOXRE into the Lumiquick Diagnostics family,” said Charles Yu, President of Lumiquick Diagnostics. “The addition of the AOXRE product line will strengthen LumiQuick’s ability to support both the clinical and research communities.”

Related Links:
Lumiquick Diagnostics
AOXRE LLC


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
8-Channel Pipette
SAPPHIRE 20–300 µL
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.